NDA 021205 · Viiv Hlthcare
Trizivir
Abacavir Sulfate, Lamivudine, Zidovudine · Oral
Accelerated approvalPriority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Feb 17, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Nov 14, 2000
Approved uses
3
Original approval plus efficacy supplements
Registered trials
239
79 Phase 3, 5 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 13, 2005 Supplement 11 · Efficacy ReviewLetterLabel
- Feb 5, 2002 Supplement 2 · Efficacy ReviewLetter
- Nov 14, 2000 Original approval · Type 3 - New Dosage Form · priority review Accelerated approvalReviewLetterLabel
1 products under this application
- TRIZIVIR · ABACAVIR SULFATE EQ 300MG BASE; LAMIVUDINE 150MG; ZIDOVUDINE 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Abacavir" as an intervention, any sponsor and status, largest first.
- Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in PakistanPivotal-lookingRecruiting
Pakistan Institute of Living and LearningAcademic, hospital or other
NCT07015944 · 26,376 participants (planned) · Start Jun 13, 2025 · Primary completion Dec 30, 2028
Drug: Standardised pharmacological treatment (antidepressants) · For: Major Depressive Disorder (MDD); Breast Cancer Survivor
Sites: Karachi, Pakistan
- Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive AdultsPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00118898 · 1,864 participants · Start Sep 2005 · Primary completion Nov 2009
Drug: Abacavir/Lamivudine; Atazanavir and 5 more · For: HIV Infections
Sites: Los Angeles, California; Palo Alto, California; San Diego, California · 52 sites in all
- Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir HypersensitivityPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00340080 · 1,806 participants · Start Apr 2006
Drug: Abacavir · For: HIV Infection
Sites: Darlinghurst, Australia; Miami, Australia; Graz, Austria · 254 sites in all
- A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000922 · 1,710 participants · Primary completion Jan 2003
Drug: Indinavir sulfate; Abacavir sulfate and 6 more · For: HIV Infections
Sites: San Francisco, California; Denver, Colorado; New Haven, Connecticut · 17 sites in all
- Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in AfricaPivotal-lookingCompleted
Medical Research CouncilGovernment (non-federal)
NCT02028676 · 1,206 participants · Start Mar 2007 · Primary completion Mar 2012
Drug: Arm A: ABC+3TC+NNRTI; Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance and 4 more · For: Human Immunodeficiency Virus
Sites: Entebbe, Uganda; Kampala, Uganda; Mulago, Uganda · 4 sites in all
- Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV InfectionPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00013520 · 1,125 participants
Drug: Abacavir sulfate, Lamivudine and Zidovudine; Atazanavir and 8 more · For: HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 60 sites in all
- Antiretroviral Therapy for Acute and Chronic HIV InfectionPivotal-lookingRecruiting
SEARCH Research FoundationAcademic, hospital or other
NCT00796263 · 900 participants (planned) · Start May 13, 2009 · Primary completion Jun 2033
Drug: HAART · For: Acute HIV Infection; Chronic HIV Infection
Sites: Bangkok, Thailand
- A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV InfectionCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000919 · 900 participants
Drug: Indinavir sulfate; Lamivudine/Zidovudine and 10 more · For: HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Menlo Park, California · 80 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Trizivir (Abacavir/Lamivudine/Zidovudine)
2024 spending
$109K
Beneficiaries
36
75 claims
Per beneficiary
$3,038
$26.60 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $789,473 |
| 2021 | $1,283,967 |
| 2022 | $1,156,681 |
| 2023 | $1,071,401 |
| 2024 | $109,370 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Equivalence Trial
- Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis.
Fichtenbaum CJ, Malvestutto CD, Watanabe MG, et al. · Lancet HIV 2025 · Randomized Controlled Trial, Multicenter Study
- Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review.
Morris SA, Alsaidi AT, Verbyla A, et al. · Clin Pharmacol Ther 2022 · Systematic Review
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, et al. · Lancet HIV 2020 · Clinical Trial, Phase III, Comparative Study
- Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy.
Andreatta K, Sax PE, Wohl D, et al. · J Antimicrob Chemother 2025 · Clinical Trial, Phase III, Comparative Study
- Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
Orkin C, Antinori A, Rockstroh JK, et al. · AIDS 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.